Hetero, one of India’s generic pharmaceutical companies, and the Russian Direct Investment Fund (RDIF) have agreed to produce over 100 million doses of Sputnik-5 Covid vaccine per year in India. They intend to produce Sputnik-5 from early next year.
In a statement from Murali Krishna Reddy, Director of International Marketing at Hetero Lab, “We are pleased to partner with RDIF to produce the most anticipated Sputnik-5 for the treatment of Kovid-19. It is another step towards our commitments in the fight against and at the same time realizing the purpose of ‘Make in India’ which has been conceived by our Prime Minister. ”
According to RDIF, the results of an interim clinical trial of the vaccine showed that it was up to 95% effective on day 42 of the first dose.
Currently a Phase III clinical trial of the vaccine has been approved, with work in progress in Belarus, the United Arab Emirates, Venezuela and the rest of the country, while the second-third phase is underway in India.
So far, requests have been received from more than 50 countries for more than 120 crore doses of Sputnik-5.